Yahoo Finance

Truist lowered the firm’s price target on Regeneron (REGN) to $940 from $975 but keeps a Buy rating on the shares. The firm is reducing its expected Eylea sales given the company’s near-term outlook, though while near-term investor focus remains on the Eylea tail, Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.

• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on REGN:

Disclaimer & DisclosureReport an Issue

• Regeneron price target lowered to $943 from $1,051 at RBC Capital

• Regeneron price target lowered to $633 from $768 at UBS

• Regeneron price target lowered to $587 from $652 at Baird

• Regeneron price target lowered to $800 from $865 at BMO Capital

• Regeneron price target lowered to $700 from $750 at Wells Fargo